Adagene (ADAG) Competitors $2.17 +0.21 (+10.71%) As of 02:40 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsFDA EventsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock ADAG vs. GOSS, ERAS, RGNX, AQST, YMAB, HUMA, VIGL, EOLS, CYRX, and MBXShould you be buying Adagene stock or one of its competitors? The main competitors of Adagene include Gossamer Bio (GOSS), Erasca (ERAS), REGENXBIO (RGNX), Aquestive Therapeutics (AQST), Y-mAbs Therapeutics (YMAB), Humacyte (HUMA), Vigil Neuroscience (VIGL), Evolus (EOLS), CryoPort (CYRX), and MBX Biosciences (MBX). These companies are all part of the "pharmaceutical products" industry. Adagene vs. Its Competitors Gossamer Bio Erasca REGENXBIO Aquestive Therapeutics Y-mAbs Therapeutics Humacyte Vigil Neuroscience Evolus CryoPort MBX Biosciences Gossamer Bio (NASDAQ:GOSS) and Adagene (NASDAQ:ADAG) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their profitability, dividends, risk, earnings, analyst recommendations, valuation, media sentiment and institutional ownership. Which has better valuation & earnings, GOSS or ADAG? Adagene has lower revenue, but higher earnings than Gossamer Bio. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioGossamer Bio$40.24M10.93-$56.53M-$0.62-3.12Adagene$103.20K990.55-$33.42MN/AN/A Does the media refer more to GOSS or ADAG? In the previous week, Adagene had 7 more articles in the media than Gossamer Bio. MarketBeat recorded 9 mentions for Adagene and 2 mentions for Gossamer Bio. Gossamer Bio's average media sentiment score of 0.45 beat Adagene's score of 0.31 indicating that Gossamer Bio is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Gossamer Bio 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Adagene 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 3 Negative mention(s) 0 Very Negative mention(s) Neutral Which has more risk & volatility, GOSS or ADAG? Gossamer Bio has a beta of 1.96, meaning that its stock price is 96% more volatile than the S&P 500. Comparatively, Adagene has a beta of 0.74, meaning that its stock price is 26% less volatile than the S&P 500. Do analysts recommend GOSS or ADAG? Gossamer Bio currently has a consensus target price of $8.50, indicating a potential upside of 339.28%. Adagene has a consensus target price of $7.00, indicating a potential upside of 222.58%. Given Gossamer Bio's higher possible upside, research analysts plainly believe Gossamer Bio is more favorable than Adagene.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Gossamer Bio 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 3.00Adagene 0 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 3.00 Do insiders & institutionals hold more shares of GOSS or ADAG? 81.2% of Gossamer Bio shares are held by institutional investors. Comparatively, 9.5% of Adagene shares are held by institutional investors. 6.7% of Gossamer Bio shares are held by insiders. Comparatively, 21.2% of Adagene shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term. Is GOSS or ADAG more profitable? Adagene has a net margin of 0.00% compared to Gossamer Bio's net margin of -344.81%. Adagene's return on equity of 0.00% beat Gossamer Bio's return on equity.Company Net Margins Return on Equity Return on Assets Gossamer Bio-344.81% -1,774.72% -46.73% Adagene N/A N/A N/A SummaryAdagene beats Gossamer Bio on 8 of the 14 factors compared between the two stocks. Get Adagene News Delivered to You Automatically Sign up to receive the latest news and ratings for ADAG and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ADAG and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ADAG vs. The Competition Export to ExcelMetricAdageneMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$102.23M$3.10B$5.75B$9.58BDividend YieldN/A2.22%4.54%4.09%P/E RatioN/A20.4830.3824.94Price / Sales990.55307.98415.42178.09Price / CashN/A42.8237.3459.16Price / Book2.717.748.936.27Net Income-$33.42M-$54.72M$3.26B$265.47M7 Day Performance31.52%-0.93%-0.31%-2.09%1 Month Performance24.00%4.23%3.69%0.30%1 Year Performance-16.22%8.95%28.52%20.65% Adagene Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ADAGAdagene2.9516 of 5 stars$2.17+10.7%$7.00+222.6%-25.5%$102.23M$103.20K0.00260Gap UpHigh Trading VolumeGOSSGossamer Bio3.6708 of 5 stars$1.73-1.5%$8.50+390.5%+105.7%$400.19M$114.70M-2.80180ERASErasca2.3258 of 5 stars$1.48+5.7%$4.57+208.9%-44.7%$396.60MN/A-2.39120News CoverageAnalyst ForecastAnalyst RevisionRGNXREGENXBIO4.4504 of 5 stars$7.46-5.0%$28.38+280.4%-35.7%$396.54M$83.33M-2.17370News CoverageAnalyst ForecastAQSTAquestive Therapeutics2.2474 of 5 stars$3.86-1.0%$10.14+162.8%-9.6%$387.38M$57.56M-6.54160YMABY-mAbs Therapeutics2.8366 of 5 stars$8.52+0.1%$11.16+31.0%-31.8%$385.36M$87.68M-17.04150Positive NewsHUMAHumacyte1.995 of 5 stars$1.75-29.4%$11.71+569.4%-74.8%$384.70M$1.57M-2.54150Analyst DowngradeGap UpHigh Trading VolumeVIGLVigil Neuroscience2.7554 of 5 stars$8.05flat$10.80+34.2%N/A$383.91MN/A-3.9340EOLSEvolus4.1446 of 5 stars$5.77-2.2%$21.25+268.3%-51.5%$381.64M$266.27M-5.89170Insider TradeCYRXCryoPort3.8652 of 5 stars$8.09+7.0%$12.00+48.3%-7.1%$379.04M$228.38M6.081,186MBXMBX Biosciences2.5623 of 5 stars$11.26-7.4%$37.63+234.1%N/A$376.35MN/A-2.4836News CoverageGap Down Related Companies and Tools Related Companies GOSS Competitors ERAS Competitors RGNX Competitors AQST Competitors YMAB Competitors HUMA Competitors VIGL Competitors EOLS Competitors CYRX Competitors MBX Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ADAG) was last updated on 8/20/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredWashington Thinks They Own Your Bank AccountWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | SponsoredNew law could create $3.7 trillion tsunami.During a meeting in Washington D.C., Jeff Brown discovered a bold initiative. He calls it “President Trump’...Brownstone Research | SponsoredHow high will gold surge?Weiss Gold Veteran Makes Shocking New Call Weiss expert Sean Brodrick went out on a limb last year and decl...Weiss Ratings | SponsoredWhat Steve Bannon revealed about Trump’s gold playA Trump advisor just said 3 words that could reset the dollar. It’s a gold move nobody saw coming—and your ...Reagan Gold Group | SponsoredThe stealth altcoin the financial world is underestimatingThis DeFi project could soar next When altcoin season fully kicks in—which the data suggests is happening R...Crypto 101 Media | SponsoredTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredCover all your expenses with just $118,000 invested?Generate up to $5,000/month with 10X less money? That's what every financial advisor tells you. But I just ...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Adagene Inc. Sponsored ADR Please log in to your account or sign up in order to add this asset to your watchlist. Share Adagene With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access